HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES

Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRPa interaction, and find use in various therapeutic, preventive or diagnostic methods. The inventi...

Full description

Saved in:
Bibliographic Details
Main Authors CHALONS-COTTAVOZ, MARIE, FALLOT, STEPHANIE, LAHMAR, MEHDI, GARRONE, PIERRE, BELTRAMINELLI, NICOLA, SCHWAMBORN, KLAUS
Format Patent
LanguageEnglish
French
Published 20.07.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRPa interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies. L'invention concerne des anticorps monoclonaux anti-CD47 humanisés, de souris ou chimériques. Ces anticorps se lient au CD47 humain glycosylé et déglycosylé avec une valeur Koff optimisée, ils perturbent l'interaction SIRPa-CD47 humain, et sont utiles dans diverses méthodes thérapeutiques, prophylactiques ou diagnostiques. L'invention comprend des anticorps isolés et des dérivés et des fragments correspondants, des formulations pharmaceutiques comprenant un ou plusieurs des anticorps monoclonaux anti-CD47 humanisés ou chimériques ; et des lignées cellulaires qui produisent ces anticorps monoclonaux. L'invention concerne également des séquences de nucléotides et d'acides aminés des anticorps.
Bibliography:Application Number: CA20173011097